The Clinical Impact of the Omicron Variant on Octogenarian Hospitalized COVID-19 Patients: The Results from CoviCamp Cohort.

Publication date: Jun 26, 2025

Introduction: This study aims to investigate the clinical impact of Omicron Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) infection on the clinical presentation of Coronavirus Disease 2019 (COVID-19) in the very old (≥80 years old) population. Methods: All patients aged 80 years or older, hospitalized from March 2020 to June 2023 with a SARS-CoV-2 infection in one of the 17 COVID-19 units in eight cities of Campania, southern Italy, were enrolled in a multicenter, observational, retrospective study. Results: 341 patients ≥ 80 years of age were included: 80 of them in the Omicron and 261 in the non-Omicron period. Patients admitted during the Omicron period were older (p = 0. 0001) and more comorbid, showing more frequently arterial hypertension (p = 0. 018), cardiovascular disease (p = 0. 0001), chronic kidney disease (CKD) (p = 0. 002), chronic obstructive pulmonary disease (COPD) (p = 0. 001), and active cancer (p = 0. 0001). Severe and critical outcomes were observed more often in the non-Omicron variant (p = 0. 0001). Patients in the Omicron group did not show a significantly prolonged hospitalization time (p = 0. 063) or a higher likelihood of death during hospitalization (p = 0. 097). Discussion: In our study, despite the greater frailty of patients hospitalized during the Omicron period, the disease appeared less severe compared to previous waves, suggesting that the lower severity of the disease could be attributed to virological rather than population characteristics. These findings underscore the importance of prevention strategies for older people, as the administration of vaccination and early antiviral therapies in at-risk subjects.

Open Access PDF

Concepts Keywords
Coronavirus aging
Hospitalization COVID-19
Italy omicron variant
June SARS-CoV-2 infection
Old

Semantics

Type Source Name
disease MESH COVID-19
disease MESH Severe Acute Respiratory Syndrome
disease MESH infection
pathway REACTOME SARS-CoV-2 Infection
disease MESH hypertension
disease MESH cardiovascular disease
disease MESH chronic kidney disease
disease MESH chronic obstructive pulmonary disease
disease MESH cancer
disease MESH death
disease MESH frailty
drug DRUGBANK Coenzyme M
disease MESH Emergency
disease MESH Infectious Diseases
disease MESH concomitant conditions
disease IDO protein
drug DRUGBANK Oxygen
disease MESH Coma
disease MESH dyspnea
disease MESH morbidity
disease MESH Comorbidity
disease MESH Overweight
disease MESH Obesity
disease MESH Dementia
disease MESH liver disease
disease MESH Ageusia
disease MESH Dysgeusia
disease MESH Anosmia
disease IDO immunodeficiency
drug DRUGBANK Creatinine
disease MESH bilirubinemia
disease IDO blood
disease IDO virulence
disease MESH respiratory failure
disease MESH interstitial pneumonia
disease MESH Sepsis
disease IDO intervention
disease IDO cell
disease MESH viral shedding
disease IDO infectivity
disease IDO replication

Original Article

(Visited 1 times, 1 visits today)